

OPINION

of a dissertation for the award of a scientific degree
"Doctor of Medical Sciences" in the field of higher education 7. Healthcare and
sports, professional direction 7.1. Medicine.

on the subject:

"A Multimodal Strategy for the Treatment of Prostate Gland Carcinoma"
Author of the dissertation: Tosho Yordanov Ganev, Ph.D., Medical University
"Prof. Dr. Paraskev Stoyanov" - Varna, Faculty of Medicine, Department of
Surgical Diseases, Department of Urology
Author of the position: Prof. Dr. Dimitar Shishkov, MD, Thrace University,
Faculty of Medicine, Department of Urology

The presented dissertation contains a total of 152 standard typewritten pages, illustrated with 26 figures and 5 tables. It is the result of the research and diagnostic and therapeutic activities of Tosho Ganev, Ph.D. It is focused thematically in the field of oncurology - carcinoma of the prostate gland. The bibliographic reference includes 518 titles. The presentation is structured correctly, in accordance with the requirements for a scientific study. The dissertation begins with a literature review, which is sufficiently extensive. It focuses on the epidemiology of prostate cancer, outlining the problem groups of patients by race and nationality. The possible etiological factors are also presented in detail, including the current from a practical point of view the question of the impact of diet on the probability of developing prostate carcinoma.

The aim of the dissertation work is clearly formulated - to analyze the multimodal treatment in high-risk carcinoma of the prostate gland. The tasks set are specific and clear, they correspond to the set goal.

The dissertation of Assoc. Dr. Tosho Ganev, MD, entitled "Multimodal strategy for the treatment of carcinoma of the prostate gland" is a systematization of both the world's scientific achievements in the field of surgical treatment of prostate cancer and the results of a retrospective study of 871 patients registered and treated in the period 1996 - 2022 in the "St. Anna" General Hospital, Varna. Factors that determine the high-risk group, as well as their weight in terms of overall survival, were statistically evaluated. Five main predictors of cancer mortality were examined: clinical progression, PSA biochemical progression, disease stage-T3-3+, GS value, and PSA values.

The results of the study showed that the overall survival of patients in the risk group was lower than that in the control group, similar results were obtained when analyzing tumor-related survival, clinical and biochemical progression-free survival. This confirms the importance of accurately determining the degree of malignancy of prostate carcinoma, which, as we know, can have many faces

and manifestations - from extremely malignant and rapidly progressing to a slow-growing tumor.

An analysis of the impact of adjuvant therapy (hormone therapy with or without radiotherapy) on the survival of patients in the risk group follows. The available data show that survival (overall, tumor-related, clinical and biochemical progression-free survival) is not statistically significantly different between patients on dual and triple therapy. These results are in line with the recommendations of the European Society of Urology that adjuvant treatment of high-risk prostate carcinoma should be individualized and tailored to the stage of the disease in each specific patient, and not applied universally and indiscriminately.

The importance of the main parameters characterizing high-risk prostate carcinoma - clinical progression (that is, the occurrence of metastases); PSA progression postoperatively; disease stage T3–4; Gleason score value >7 and PSA values >20.

The 77-page abstract of the dissertation presented to me is designed according to the generally accepted requirements.

Based on the research, the author has made 7 reliable conclusions and has 7 original contributions.

No significant critical remarks can be made to the dissertation work.

This scientific work is entirely the author's work and has all the qualities and requirements for awarding the scientific degree "Doctor of Medical Sciences" to Assoc. Tosho Ganev, MD. That is why, internally convinced, I recommend the members of the respected scientific jury to vote positively.

29.10.2023

Signature:.....
Prof. Dr. Dimitar Shishkov, dm